Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1988 1
1991 1
1992 3
1993 2
1994 1
1995 4
1996 3
1997 5
1998 7
1999 6
2000 5
2001 7
2002 5
2003 17
2004 14
2005 9
2006 11
2007 15
2008 23
2009 12
2010 12
2011 9
2012 3
2013 8
2014 4
2015 8
2016 9
2017 2
2018 5
2019 4
2020 2
2021 1
2022 2
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Results by year

Filters applied: . Clear all
Page 1
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, Nakamura M, Kotaka M, Sugimoto N, Ojima H, Oki E, Kajiwara T, Yamamoto Y, Tsuji Y, Denda T, Tamura T, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Sunakawa Y, et al. Among authors: shirao k. Target Oncol. 2024 Jan;19(1):59-69. doi: 10.1007/s11523-023-01027-8. Epub 2024 Jan 9. Target Oncol. 2024. PMID: 38194163 Free PMC article. Clinical Trial.
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Kuboki Y, et al. Among authors: shirao k. Br J Cancer. 2023 May;128(10):1897-1905. doi: 10.1038/s41416-023-02212-2. Epub 2023 Mar 4. Br J Cancer. 2023. PMID: 36871043 Free PMC article. Clinical Trial.
Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor.
Amada K, Hijiya N, Ikarimoto S, Yanagihara K, Hanada T, Hidano S, Kurogi S, Tsukamoto Y, Nakada C, Kinoshita K, Hirashita Y, Uchida T, Shin T, Yada K, Hirashita T, Kobayashi T, Murakami K, Inomata M, Shirao K, Aoki M, Takekawa M, Moriyama M. Amada K, et al. Among authors: shirao k. Cancer Sci. 2023 May;114(5):2189-2202. doi: 10.1111/cas.15735. Epub 2023 Feb 9. Cancer Sci. 2023. PMID: 36694355 Free PMC article.
A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site.
Nishikawa K, Hironaka S, Inagaki T, Komori A, Otsu S, Mitsugi K, Makiyama A, Watanabe K, Tamura S, Okumura Y, Kusaba H, Esaki T, Baba E, Shirao K. Nishikawa K, et al. Among authors: shirao k. Jpn J Clin Oncol. 2022 Dec 5;52(12):1416-1422. doi: 10.1093/jjco/hyac143. Jpn J Clin Oncol. 2022. PMID: 36047806 Review.
Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K. Hatake K, et al. Among authors: shirao k. Jpn J Clin Oncol. 2016 Mar;46(3):234-40. doi: 10.1093/jjco/hyv182. Epub 2016 Jan 15. Jpn J Clin Oncol. 2016. PMID: 26774113
Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids.
Tsukamoto Y, Kurogi S, Shibata T, Suzuki K, Hirashita Y, Fumoto S, Yano S, Yanagihara K, Nakada C, Mieno F, Kinoshita K, Fuchino T, Mizukami K, Ueda Y, Etoh T, Uchida T, Hanada T, Takekawa M, Daa T, Shirao K, Hironaka S, Murakami K, Inomata M, Hijiya N, Moriyama M. Tsukamoto Y, et al. Among authors: shirao k. Lab Invest. 2022 Dec;102(12):1355-1366. doi: 10.1038/s41374-022-00827-2. Epub 2022 Aug 3. Lab Invest. 2022. PMID: 35922477 Free article.
Toxoplasmic Encephalitis with Untreated Hairy Cell Leukemia Variant.
Ikebe T, Sasaki H, Takata H, Miyazaki Y, Ohtsuka E, Saburi Y, Ogata M, Shirao K. Ikebe T, et al. Among authors: shirao k. Intern Med. 2016;55(21):3175-3180. doi: 10.2169/internalmedicine.55.6668. Epub 2016 Nov 1. Intern Med. 2016. PMID: 27803415 Free PMC article.
207 results